Method for determining the response to cancer therapy

Details Method for determining the response to cancer therapy Method for determining the response to cancer therapy

2001-01-12

2010-11-16

Canella, Karen A (Department: 1643)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

C435S007100, C435S007400, C435S007920, C436S063000, C436S064000, C436S503000

Reexamination Certificate

active

07833698

ABSTRACT:
The invention relates to a method for determining the response to cancer therapy in an individual using image analysis.

REFERENCES:
patent: 4741043 (1988-04-01), Bacus
patent: 5389523 (1995-02-01), Plant et al.
patent: 5498522 (1996-03-01), Porter
patent: 5536642 (1996-07-01), Barbera-Guillem et al.
patent: 5665549 (1997-09-01), Pinkel et al.
patent: 5772998 (1998-06-01), Dasch et al.
patent: 5852035 (1998-12-01), Pamukcu
patent: 5935801 (1999-08-01), Schlossman et al.
patent: 5972622 (1999-10-01), Desjardins
patent: 6350452 (2002-02-01), Riss
patent: 6372895 (2002-04-01), Bentsen et al.
patent: 6447997 (2002-09-01), Los et al.
patent: 2004/0058320 (2004-03-01), Roninson et al.
patent: WO 99/16789 (1999-04-01), None
patent: WO 99/24620 (1999-05-01), None
The abstract of Bacus et al (Breast Cancer research and Treatment, 1999, vol. 57, p. 55).
Warri et al (Journal of the National cancer Institute, 1993, vol. 85, pp. 1412-1418.
The abstract of Fornier et al (Oncology, 1999, vol. 13, p. 647-658.
The abstract of Lebwhol et al (Annals of Oncology, 1999, 10 suppl. 6, pp. 139-146).
Caffo et al (Clinical Cancer research, 1996, vol. 2, pp. 1591-1599.
The abstract of el-Deiry et al (Cancer Research, 1995, vol. 55, pp. 2910-2919).
The abstract of Thor et al (Journal of the National cancer Institute, 1992, vol. 84, pp. 845-855).
The abstract of Shetty et al (Leukemia Research, 1996, vol. 20, pp. 11-12).
Hochhauser (Anti-Cancer Drugs, 1997, vol. 8, pp. 903-910).
The abstract of Ohtani et al (Cancer, 1999, vol. 85, pp. 1711-1718).
The abstract of Emig et al (British Journal of Cancer, 1998, vol. 78, pp. 1661-1668).
Meyn et al (Anticancer Drugs, 1995, vol. 6, pp. 443-450).
The abstract of Booth et al (Apoptosis, 1996, vol. 1, pp. 191-200).
The abstract of Shen et al (Cancer, 1998, vol. 82, pp. 2373-2381).
The abstract of Hiraishi et al, Glycobiology, 1993, vol. 3, pp. 381-390).
The abstract of Cutrona et al(Journal of Experimental Medicine, 1995, vol. 181, pp. 699-711).
The abstract of Frankfurt et al (anticancer Research, 1996, vol. 16, pp. 1979-1988).
The abstract of Attallah et al (Hepato-Gastroenterology, 1996, vol. 43, pp. 1305-1312).
The abstract of Smith and al-Mounhri (Biomed Pharmacother, 1998, vol. 52, pp. 116-121).
The abstract of Vollmer et al (Cancer Research, 1992, vol. 52, pp. 4642-4648).
The abstract of Dannecker et al (Ann Oncol, 1996, vol. 7, pp. 391-395).
The abstract of Kopp et al (Cancer Research, 1995, vol. 55, pp. 4512-4515).
Sasaki et al (Jpn J Cancer Research, 1998, vol. 89, pp. 562-570).
The abstract of Srivastava et al (Anticancer Res, 1998, vol. 18, pp. 4003-4010).
The abstract of Gillett et al. (J Pathol. Jan. 1999;187(2):200-6).
The abstract of Emig et al (Br J Cancer. 1998, vol. 78, pp. 1661-1668).
DeVita (Cancer, Principles & Practice of Oncology, 2001, pp. 345-356).
Morris et al (Biochemical and Molecular Medicine, 1997, vol. 60, pp. 108-115).
Abstract of Sethi et al (Proc Annu Meet Am Soc Clin Oncol, 1996, vol. 15, pp. A1308).
Urashima et al (Blood, 1997, vol. 90, pp. 4106-4115).
Wang et at (International Journal of Oncology, 1999, vol. 15, pp. 1097-1102).
Li et al (Leukemia and Lymphoma, 1994, vol. 13, suppl. 1, pp. 65-70).
Abstract of Cen et al, Zhonghua nei ke za zhi [Chinese Journal of Internal Medicine] 1997, vol. 36, pp. 300-303.
Cohen et al (Biochemical Society Symposium, 1998, vol. 63, pp. 199-210).
Abstract of Bacus et al (Proc Annu Meet Am Assoc Cancer Res, 1996, vol. 37, A3945).
Chang et al (Cancer Research, 1999, vol. 59, pp. 3761-3767).
Eymin et al (Oncogene, 1999, vol. 18, pp. 1411-1418).
Dragnev et al, The Oncologist, 2000, vol. 5, pp. 361-368.
Dimiri et al, PNAS, 1995, vol. 92, pp. 9363-9367.
Park et al (Journal of Cancer Research and Clinical Oncology, 2000, vol. 126, pp. 455-460).
Butta et al (Cancer Research, 1992, vol. 52, pp. 4261-4264).
Comerci et al (Clinical Cancer Research, 1997, vol. 3, pp. 157-160).
Cada et al Ed.s, Drug Facts and Comparisons, 1999, p. 3283.
Bacus et al., “Neu differentiation factor (Heregulin) activates a p53-dependent pathway in cancer cells,” Oncogene 12(12):2535-47, 1996.
Chang et al., “p21Waf1/Cip1/Sdi1-induced growth arrest is associated with depletion of mitosis-control proteins and leads to abnormal mitosis and endoreduplication in recovering cells,” Oncogene 19:2165-2170, 2000.
Kopp et al., “Transforming Growth Factor β2 (TGF-β2) Levels in Plasma of Patients with Metastatic Breast Cancer Treated with Tamoxifen,” Cancer Research 55(20):4512-4515, 1995.
Lei et al., “The expression of suppressor gene p16, p21 and p53 in nasopharyngeal carcinoma,” Lin Chuang Er Bi Yan Hou Ke Za Zhi 13(9):406-8, 1999.
Meyn et al., “Apoptosis in murine tumors treated with chemotherapy agents,” Anti-Cancer Drugs 6:443-450, 1995.
Shibata et al., “Suppression of mammary carcinoma growth in vitro and in vivo by inducible expression of the Cdk inhibitor p21,” Cancer Gene Therapy 8:23-35, 2001.
Timmermann et al., “Re-expression of endogenous p16ink4ain oral squamous cell carcinoma lines by 5-aza-2′-deoxycytidine treatment induces a senescence-like state,” Oncogene 17(26):3445-53, 1998.
Dannecker et al.; Induction of TGF-beta by an antiprogestin in the human breast cancer cell line T-47D; Ann. Onc., Apr. 1996; 7: 391-395.
Gillett et al.; Cyclin-dependent kinase inhibitor p27Kip1 expression and interaction with other cell cycle-associated proteins in mammary carcinoma; J Pathol, Jan. 1999; 187(2): 200-6.
Smith et al.; Primary chemotherapy in breast cancer, Biomed Pharmacother, Jan. 1998; 52(3): 116-21.
Srivastava et al.; Growth inhibition and activation of apoptotic gene expression by human chorionic gonadotropin in human breast epithelial cells; Anticancer Res, Nov. 1998; 18(6A): 4003-10.
Vollmer et al.; Down-regulation of tenascin expression by antiprogestins during terminal differentiation of rat mammary tumors; Cancer Res., Sep. 1992; 52: 4642-4648.

Affiliated with

Also associated with

Rating

Method for determining the response to cancer therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method for determining the response to cancer therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for determining the response to cancer therapy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4251390